Hi BearDownAZ. Thanks for the post and your point about the patent issue i.e. I wonder who is onto it and how fast they are moving.

I haven't relistened to the presentation there were many positive points. I get the impression that Zenith has gained some credibility in the scientific community. Don mentioned (I think) some collaboration with Sloan Kettering. He mentioned quick FDA approvals because of the ZEN platforms. He talked about many platforms in development and he discussed the approach where they can now assess an individual's genes and tailor BET inhibitor to specific people and diseases. He mentioned possible proof of concept at phase 1.

I'm not a scientist but if I accept Don at his word the presentation left me very hopeful and hopeful about rvx-208 because Zenith's genesis was at RVX.

I'm looking forward to hear opinions from those that have had time to review it further over the next few days.

Cheers

Toinv